Shopping Cart 0
Cart Subtotal
AED 0

Probiogen AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Probiogen AG (Probiogen) a subsidiary of Minapharm Pharmaceuticals & Chemical Industries is a contract development and manufacturing organization that offers cell line engineering, process development and GMP manufacturing of biopharmaceuticals. The organization's services comprise therapeutic proteins/antibodies, viral vaccines, biosimilar and biobetter development. It offers contract cell line development, contract process development, contract manufacturing of GMP and non-GMP, protein analytics, and cell-based assays. It develops various technologies for optimized biopharmaceutical manufacturing and analysis. The organization also develops virusproduction system, adcc enhancement, yield enhancement, innovative bioassays and other technologies. Probiogen is headquartered in Berlin, Germany.

Probiogen AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Probiogen AG, Medical Devices Deals, 2012 to YTD 2018 9

Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Probiogen AG, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

ProBioGen Enters into Agreement with Tizona Therapeutics 11

ProBioGen Enters into Agreement with Surface Oncology 12

ProBioGen Enters into Co-Development Agreement with PT Bio Farma 13

ProBioGen Enters into Agreement with Zymeworks 14

Licensing Agreements 15

Nouscom Enters into Licensing Agreement with ProBioGen 15

Chiome Bioscience Enters into Licensing Agreement with ProBioGen 16

ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 17

ProBioGen Enters into Licensing Agreement with Merus 18

ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 19

ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 20

ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 21

Probiogen AG-Key Competitors 22

Probiogen AG-Key Employees 23

Probiogen AG-Locations And Subsidiaries 24

Head Office 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Probiogen AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Probiogen AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Probiogen AG, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Probiogen AG, Pharmaceuticals & Healthcare, Key Facts 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Probiogen AG, Deals By Therapy Area, 2012 to YTD 2018 8

Probiogen AG, Medical Devices Deals, 2012 to YTD 2018 9

Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProBioGen Enters into Agreement with Tizona Therapeutics 11

ProBioGen Enters into Agreement with Surface Oncology 12

ProBioGen Enters into Co-Development Agreement with PT Bio Farma 13

ProBioGen Enters into Agreement with Zymeworks 14

Nouscom Enters into Licensing Agreement with ProBioGen 15

Chiome Bioscience Enters into Licensing Agreement with ProBioGen 16

ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 17

ProBioGen Enters into Licensing Agreement with Merus 18

ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 19

ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 20

ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 21

Probiogen AG, Key Competitors 22

Probiogen AG, Key Employees 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Probiogen AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Probiogen AG (Probiogen) a subsidiary of Minapharm Pharmaceuticals & Chemical Industries is a contract development and manufacturing organization that offers cell line engineering, process development and GMP manufacturing of biopharmaceuticals. The organization's services comprise therapeutic proteins/antibodies, viral vaccines, biosimilar and biobetter development. It offers contract cell line development, contract process development, contract manufacturing of GMP and non-GMP, protein analytics, and cell-based assays. It develops various technologies for optimized biopharmaceutical manufacturing and analysis. The organization also develops virusproduction system, adcc enhancement, yield enhancement, innovative bioassays and other technologies. Probiogen is headquartered in Berlin, Germany.

Probiogen AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Probiogen AG, Medical Devices Deals, 2012 to YTD 2018 9

Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Probiogen AG, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

ProBioGen Enters into Agreement with Tizona Therapeutics 11

ProBioGen Enters into Agreement with Surface Oncology 12

ProBioGen Enters into Co-Development Agreement with PT Bio Farma 13

ProBioGen Enters into Agreement with Zymeworks 14

Licensing Agreements 15

Nouscom Enters into Licensing Agreement with ProBioGen 15

Chiome Bioscience Enters into Licensing Agreement with ProBioGen 16

ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 17

ProBioGen Enters into Licensing Agreement with Merus 18

ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 19

ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 20

ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 21

Probiogen AG-Key Competitors 22

Probiogen AG-Key Employees 23

Probiogen AG-Locations And Subsidiaries 24

Head Office 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Probiogen AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Probiogen AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Probiogen AG, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Probiogen AG, Pharmaceuticals & Healthcare, Key Facts 2

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Probiogen AG, Deals By Therapy Area, 2012 to YTD 2018 8

Probiogen AG, Medical Devices Deals, 2012 to YTD 2018 9

Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProBioGen Enters into Agreement with Tizona Therapeutics 11

ProBioGen Enters into Agreement with Surface Oncology 12

ProBioGen Enters into Co-Development Agreement with PT Bio Farma 13

ProBioGen Enters into Agreement with Zymeworks 14

Nouscom Enters into Licensing Agreement with ProBioGen 15

Chiome Bioscience Enters into Licensing Agreement with ProBioGen 16

ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 17

ProBioGen Enters into Licensing Agreement with Merus 18

ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 19

ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 20

ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 21

Probiogen AG, Key Competitors 22

Probiogen AG, Key Employees 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Probiogen AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.